Breaking: Ampliphi Biosciences (APHB) “Buy” Rating Reaffirmed at H.C. Wainwright Today; The Price Target is $6.0000

May 16, 2018 - By Darrin Black

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Logo

Ampliphi Biosciences (APHB) Rating Reaffirmed

In an analyst report made public this morning, H.C. Wainwright reconfirmed their “Buy” rating on Ampliphi Biosciences (APHB) shares. The PT would suggest a possible upside of 450.46 % from company’s stock close price.

The stock decreased 7.92% or $0.09 during the last trading session, reaching $1.09. About 273,453 shares traded. AmpliPhi Biosciences Corporation (APHB) has declined 77.34% since May 17, 2017 and is downtrending. It has underperformed by 88.89% the S&P500.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage technology. The company has market cap of $17.95 million. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. It currently has negative earnings. The firm has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.